Bispecific Antibodies in the Management of Lymphoma — ASH 2025 Review
Échec de l'ajout au panier.
Veuillez réessayer plus tard
Échec de l'ajout à la liste d'envies.
Veuillez réessayer plus tard
Échec de la suppression de la liste d’envies.
Veuillez réessayer plus tard
Échec du suivi du balado
Ne plus suivre le balado a échoué
Bispecific Antibodies in the Management of Lymphoma — ASH 2025 Review
-
Narrateur(s):
-
Auteur(s):
À propos de cet audio
Featuring perspectives from Prof Michael Dickinson and Dr Laurie H Sehn, including the following topics:
- Introduction (0:00)
- Future Treatment of Non-Hodgkin Lymphoma (NHL) (2:24)
- Case: A man in his mid 60s with diffuse large B-cell lymphoma (DLBCL) and early relapse on axicabtagene ciloleucel receives glofitamab — Dr Sehn (8:10)
- Case: A man in his late 60s with Type 2 diabetes, congestive heart failure and chronic obstructive pulmonary disease receives glofitamab monotherapy after glofitamab with gemcitabine/oxaliplatin for relapsed GCB-type double-hit DLBCL — Matthew Lunning, DO (14:54)
- Practical Perspectives on the Current Role of Bispecific Antibodies in the Management of Lymphoma — Prof Dickinson (18:00)
- Case: A woman in her mid 50s with multiregimen-recurrent follicular lymphoma (FL) receives mosunetuzumab — Carla Casulo, MD (35:33)
- Case: A man in his late 70s with multiregimen-refractory FL receives mosunetuzumab with an ongoing complete response — Dr Sehn (40:05)
- FL and Other NHL Subtypes — Dr Sehn (45:30)
CME information and select publications
Pas encore de commentaire